

A Molecular Model for Lithium's Bioactive Form

Katharine T. Briggs,¹ Gary G. Giulian,¹ Gong Li,^{2,3} Joseph P. Y. Kao,^{2,4} and John P. Marino^{1,*}

¹Institute for Bioscience and Biotechnology Research, University of Maryland, National Institute of Standards and Technology, Rockville, Maryland; ²Center for Biomedical Engineering and Technology, University of Maryland School of Medicine, Baltimore, Maryland; ³Department of Neural and Pain Sciences, University of Maryland School of Dentistry, Baltimore, Maryland; and ⁴Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland

ABSTRACT Lithium carbonate, a drug for the treatment of bipolar disorder, provides mood stability to mitigate recurrent episodes of mania and/or depression. Despite its long-term and widespread use, the mechanism by which lithium acts to elicit these psychological changes has remained unknown. Using nuclear magnetic resonance (NMR) methods, in this study we characterized the association of lithium with adenosine triphosphate (ATP) and identified a bimetallic (Mg·Li) ATP complex. Lithium's affinity to form this complex was found to be relatively high ($K_d \sim 1.6$ mM) compared with other monovalent cations and relevant, considering lithium dosing and physiological concentrations of Mg^{2+} and ATP. The ATP·Mg·Li complex reveals, for the first time, to the best of our knowledge, that lithium can associate with magnesium-bound phosphate sites and then act to modulate purine receptor activity in neuronal cells, suggesting a molecular mode for in vivo lithium action.

INTRODUCTION

Lithium (Li^+) has been used for treating various ailments since the 1850s and was first repurposed to treat “psychotic excitement” by John Cade in 1949 (1,2). Shortly after its approval by the Food and Drug Administration (FDA) in 1970, it was proposed that Li^+ may act through a “challenge” to other biological cations [e.g., sodium (Na^+), potassium (K^+), calcium (Ca^{2+}), magnesium (Mg^{2+})] and thereby cause a biological effect (3). Support for the challenge hypothesis came from early research that showed that under experimental conditions that simulated complex biological media where many molecules compete for binding to these cations, Li^+ could compete with Mg^{2+} for its binding sites. Under such simulated conditions created with cation-sequestering agents, like ATP, it was shown that Li^+ could challenge Mg^{2+} for binding to uramildiacetate (4), a complexing agent derived from urea and an iminopolycarboxylic acid, where Mg^{2+} is normally preferred (3).

Subsequently, the interpretation of these experiments was challenged on the basis of a failure to consider that Li^+ might also bind to the ATP present in the medium (5). Further nucleotide binding studies (6) suggested that Li^+ could associate with nucleotides in the presence of Mg^{2+} , which led to the hypothesis that Li^+ may act therapeutically

by interrupting ATP/ADP equilibria in key enzymes, such as ATPases. Although these preliminary studies suggested the possibility of a ternary complex comprising Li^+ , Mg^{2+} , and nucleotide, confirmation of the exact nature of this complex required more direct physical evidence (6). Moreover, despite subsequent biochemical and biophysical studies (7–9), a consensus on the mode of Li^+ interaction was never reached, nor have the enzymes found to be inhibited by Li^+ , such as glycogen synthase kinase 3 β (GSK3 β) and inositol monophosphatase (IMPase) (10), been validated as the target of Li^+ in treatment of bipolar disorder.

In this study we demonstrate, using solution-state NMR techniques, that Li^+ can indeed associate with magnesium-chelated nucleotides (NDP/NTP) under physiological cation concentrations. This has led to the hypothesis that a purine receptor response might be modulated by an ATP·Mg·Li complex and more generally provides a common molecular framework for how lithium may adopt its bioactive form by cobinding to magnesium-bound phosphorylated ligands or cofactors.

MATERIALS AND METHODS

Certain commercial equipment, instruments, and materials are identified in this article to specify the experimental procedure. Such identification does not imply recommendation or endorsement by the National Institute of Standards and Technology (NIST), nor does it imply that the material or equipment identified is necessarily the best available for the purpose.

Submitted December 21, 2015, and accepted for publication June 10, 2016.

*Correspondence: john.marino@nist.gov

Editor: Jeff Peng

<http://dx.doi.org/10.1016/j.bpj.2016.06.015>

NMR sample preparation

NMR samples were prepared in 5 mm NMR tubes (Wilmad Labglass, Vine-land, NJ) with a H₂O/D₂O (9:1) mixture to a final volume of 500 μ L (D₂O from Cambridge Isotope Laboratories, Tewksbury, MA). Dry stocks of the sodium salts of adenosine triphosphate, adenosine diphosphate, guanosine triphosphate, guanosine diphosphate, triphosphate (Sigma-Aldrich, St. Louis, MO) were dissolved in water at 100 mM, adjusted to pH 8.0 with NaOH and stored at -20°C until ready for use. A standard pH meter and probe were used (series Φ pH meter from Beckman, Brea, CA; Orion pH electrode from Thermo Scientific, Waltham, MA). Samples were prepared in NMR buffer (25 mM sodium chloride and 1 mM sodium cacodylate, pH 6.5) from a 10 \times stock. Sodium chloride, sodium cacodylate, lithium chloride solution (8 M), magnesium chloride hexahydrate, and manganese (II) chloride tetrahydrate were purchased from Sigma-Aldrich. Unless otherwise stated, NMR samples contained 10 mM ATP (50 μ L of 100 mM stock), 11 mM MgCl₂ (5.5 μ L of 1M MgCl₂ stock), 10 mM LiCl (5 μ L of 1M LiCl stock), with or without 50 μ M MnCl₂ (2.5 μ L from 10 mM MnCl₂ stock), 50 μ L D₂O, and brought up to 500 μ L with NMR buffer.

NMR data collection

Data were collected on a Bruker (Billerica, MA) 600 MHz AVANCE spectrometer with a broadband observe (BBFO) probe, a Bruker 500 MHz DRX spectrometer with a broadband probe, or a Bruker 600 MHz AVANCE spectrometer equipped with a broadband inverse probe. Datasets were collected

Lithium titration binding measurements by NMR

Li⁺ binding affinity to ATP was determined by a series of ⁷Li inversion recovery experiments measuring the ⁷Li T1 relaxation (2 mM LiCl in buffer) with increasing concentrations of ATP·Mg (Mn). The Bruker automation software, IconNMR, was used with the Bruker automation hardware, NMR Case, for acquisition of the multiple samples required to generate each ⁷Li T1 relaxation data point and the T1 relaxation was determined using the Topspin "T1Guide" software. Further details on the measurement of ⁷Li T1 relaxation is as described in the previous experimental section. The ⁷Li T1 relaxation data were plotted and fit using a nonlinear equation in GraFit 5 (Erithacus Software, East Grinstead, UK). Each observed ⁷Li T1 signal (T_{obs}) was interpreted using a two-state model where the two states refer to free and ATP·Mg-bound Li⁺, and treated as the population-weighted average of the signals from the following two states:

$$T_{obs} = T_f f_f + T_b f_b \quad (1)$$

where T_f represents the free Li⁺ NMR ⁷Li T1 constant, f_f represents the fraction of free Li⁺, T_b represents the ATP·Mg-bound Li⁺ NMR ⁷Li T1 constant, and f_b represents the fraction of ATP·Mg-bound Li⁺.

$$T_{obs} = T_f - \frac{(T_f - T_b)x}{[Li_0]} \quad (2)$$

where

$$x = \frac{(K_D + [Li_0] + [ATP_0]) - \sqrt{(K_D + [Li_0] + [ATP_0])^2 - 4([Li_0][ATP_0])}}{2}, \quad (3)$$

at 283 K (9.85°C), 298 K (24.85°C), 300 K (26.85°C), 303 K (29.85°C), or 310 K (36.85°C) and data are presented in the text with specific temperatures of acquisition.

⁷Li T1 relaxation measurements

One-dimensional (1D) ⁷Li NMR inversion recovery experiments were used to measure T1 relaxation with the following experimental acquisition parameters unless otherwise noted in the text: pre-delay (D1) of roughly five times the ⁷Li T1, which was measured at each temperature and typically exceeded 100 s. The total digitization (TD) was 4096 points, sweep width 699.63, dummy scans (DS) = 4, number of scans (NS) = 8, with a spectrometer frequency of 233.233 MHz for lithium at 14.4 Tesla (600 MHz proton frequency spectrometer). The variable delay list was kept constant for comparable sets of experiments but may otherwise be different depending on the expected relaxation rate (i.e., experiments at different temperatures). Spectra collected at different delay times were processed with the same zero filling to 2 \times the number of data points, apodized with exponential multiplication using 2.0 Hz line broadening, and phase corrected based on the zero time delay of the variable delay. The lithium signal was peak picked, the peak height and integrated volume of the signal was then measured and plotted for each experiment at the different variable delays to allow fitting to a T1 relaxation rate using Topspin 1.3 with the following commands: "xf2," "t1guide," "extract slice" from FID number 32, "define ranges" to obtain integral, export region to relaxation module, "relaxation window" to plot data, and fit the data.

and $[Li_0]$ is the total Li⁺ concentration and $[ATP_0]$ is the total concentration of ATP·Mg, except in the Li⁺ control experiment (Fig. S3 in the Supporting Material), where $[ATP_0]$ is the total concentration of ATP.

³¹P NMR measurements

The ³¹P 1D experiments used a zero go pulse program with the broadband probe tuned to 242.93 MHz for phosphorus at 14.4 Tesla (600 MHz proton frequency spectrometer), number of scans (NS) = 1024, dummy scans (DS) = 4, and total digitization (TD) = 8192. Spectra were processed with zero filling to 2 \times the number of data points and apodized with a cosine function over 512 points.

[Ca²⁺]_i measurements on rat neurons

Male Sprague-Dawley rats, weighing 150–250 g, were purchased from Harland Laboratories (Frederick, MD) and killed by CO₂ asphyxiation, as approved by the Institutional Animal Care and Use Committee of the University of Maryland Biotechnology Institute. Dissociation of nodose ganglion neurons (NGNs) was performed as described previously (11) with the exception that sterile technique was used and the final neuronal pellet was resuspended in Leibovitz L-15 medium (Gibco-BRL, Grand Island, NY) containing 10% fetal bovine serum (FBS; JRH Bioscience, Lenexa, KS). The resulting cell suspension was plated as 0.2 mL aliquots onto 25 mm glass cover slips (Fisher Scientific, Newark, DE) coated with poly-D-lysine (0.1 mg/mL; Sigma). NGNs were incubated at 37°C for

24 h, then maintained at room temperature to prevent neurite outgrowth, and used for experiments for 72 h. NGNs were loaded with fluo-3 by incubation with the acetoxymethyl (AM) ester of fluo-3, as previously described (12). During imaging experiments, the neurons were superfused with Locke solution containing the following (in mM): 120 NaCl, 3.0 KCl, 1.5 MgCl₂, 1.0 NaH₂PO₄, 25 NaHCO₃, 2.5 CaCl₂, and 10.0 dextrose; the solution was equilibrated with 95% O₂/5% CO₂ to reach a final pH of 7.4. Where nominally Ca²⁺-free solution was required, CaCl₂ was replaced with an equivalent amount of MgCl₂. P2 receptor activation was induced by exposure to 100 μM ATP, 100 μM MgCl₂, and 1 mM LiCl in the superfusate as specified in the data. A laser scanning confocal microscope (LSM 510 NLO; Carl Zeiss Microscopy, Jena, Germany) was used to image changes in fluo-3 fluorescence elicited by agonist challenges in the NGNs. Fluorescence excitation was at 490 nm and other experimental parameters with fluo-3 detection were performed as described previously (12). After background correction, fluorescence intensity change was reported relative to the baseline fluorescence ($\Delta F/F_0$). Student's *t*-test was applied to the data to determine significance between two means.

Structures and graphs

ATP structures were built using ChemBioDraw (Perkin Elmer, Waltham, MA) and annotated with CorelDraw X7 (Corel, Ottawa, Canada).

RESULTS AND DISCUSSION

In this study, the question of Li⁺ binding to ATP (13) in the presence of Mg²⁺ has been readdressed using ⁷Li NMR (Fig. 1 A). To ensure a known and invariant ATP·Mg concentration, Mg²⁺ was used at saturating concentration (10 mM ATP, 11 mM MgCl₂); saturation was confirmed by ³¹P NMR, which can monitor Mg²⁺ binding through changes in the chemical shifts of the nucleotide phosphorus atoms (Fig. S1). Under these conditions, addition of a stoichiometric amount of Li⁺ can have three possible outcomes (Fig. 1 B): 1) no Li⁺ binding to ATP·Mg; 2) Li⁺ binding to ATP by displacing the Mg²⁺; or 3) Li⁺ binding to ATP·Mg without displacing the Mg²⁺. To distinguish these possibilities, the ⁷Li T1 relaxation time was measured in the presence of ATP·Mg and compared with reference values obtained in buffer alone. If Li⁺ binds to ATP·Mg and the Li⁺ population shifts from being free to nucleotide-bound, then T1 would be expected to be shorter than that measured in buffer alone. Fig. 1 C shows representative ⁷Li T1 inversion-recovery data (open circles) where Li⁺ peak intensity is plotted as a function of relaxation delay, which reveals the extent that the signal has returned to the equilibrium value after application of a 180-degree inversion pulse. Single-exponential fits to the data yielded T1 values. Thus, whereas the reference ⁷Li T1 for 10 mM LiCl and 11 mM MgCl₂ in buffer alone was 12.96 s at 10°C (Table S1), the ⁷Li T1 for 10 mM LiCl in the presence of 10 mM ATP and 11 mM MgCl₂ was 7.16 s. The nearly twofold change in T1 indicates measurable Li⁺ binding to ATP.

Although the change in ⁷Li T1 indicates that Li⁺ binds to ATP in the presence of Mg²⁺, this measurement does not reveal whether Li⁺ binding displaces Mg²⁺ (competition). To address the latter question, manganese (Mn²⁺), which




FIGURE 1 Mode of Li⁺ binding to ATP·Mg. (A) Schematic representation of ATP with Mg²⁺ bound to the β and γ phosphates is shown. (B) Three possible modes of Li⁺ binding to ATP·Mg (phosphates, red; Mg²⁺, blue; Li⁺, green) are shown. Scheme 1 represents Li_f + ATP·Mg → ATP·Mg + Li_f. Scheme 2 represents Li_f + ATP·Mg → ATP·Li + Mg_f. Scheme 3 represents Li_f + ATP·Mg → ATP·Mg·Li. (C) Representative ⁷Li T1 relaxation data in the absence (open circles) and presence (closed circles) of 50 μM MnCl₂ in a sample of 10 mM ATP, 11 mM MgCl₂, and 10 mM LiCl; smooth curves are single-exponential fits.

can bind nucleotide triphosphates in a manner similar to Mg²⁺, was spiked into the buffer as a paramagnetic probe (14). Because of the fast exchange kinetics (> 10,000 s⁻¹) of Mg²⁺/Mn²⁺ binding to ATP, rapid sampling of all the ATP molecules by the two divalent cations was observed even at a Mg²⁺:Mn²⁺ molar ratio of 220:1 (Fig. S2). Since the electron magnetic dipole moment of Mn²⁺ is known to cause a paramagnetic relaxation enhancement (PRE) to all

NMR-active nuclei within ~ 30 Å, observation of a ^7Li T1 PRE would indicate that the sites being sampled by Mn^{2+} are proximal to the Li^+ binding sites, and is thus evidence of two-metal binding (Fig. 1 B, Scheme 3). Conversely, ^7Li T1 PRE would not be observed if $\text{Mg}^{2+}/\text{Mn}^{2+}$ is displaced into solution upon Li^+ binding (Fig. 1 B, Scheme 2). Addition of $50 \mu\text{M}$ MnCl_2 to a sample of 10 mM ATP, 11 mM MgCl_2 , and 10 mM LiCl caused marked PRE—shortening the ^7Li T1 from 7.16 to 2.30 s (Fig. 1 C; Table S1). This observation provides direct evidence that under conditions of saturating, stoichiometric binding of Mg^{2+} , Li^+ does not displace Mg^{2+} from ATP, but rather co-binds in proximity to the divalent cation ($\text{Mg}^{2+}/\text{Mn}^{2+}$). In contrast, the addition of Mn^{2+} to a sample of Li^+ and Mg^{2+} in buffer without ATP yielded a ^7Li T1 of 12.24 s —only slightly shorter ($\sim 5\%$) than the T1 measured in the absence of Mn^{2+} (Table S1); such a small change is within the uncertainty of the measurement. The observation of the Li^+ binding to $\text{ATP}\cdot\text{Mg}$ led to the question of whether a nucleoside diphosphate would similarly bind Mg^{2+} and Li^+ , and whether the adenine and ribose moieties are necessary for metal ion binding. To address these questions, ^7Li T1 relaxation inversion-recovery experiments were performed with adenosine 5'-diphosphate (ADP) and triphosphate (TP) (Table S1) in the presence of Mg^{2+} . Like ATP, these molecules are known to chelate Mg^{2+} (15,16) and to interact with Li^+ in its presence. Just as was observed for ATP, trace Mn^{2+} in these samples caused ^7Li T1 PRE. These experiments showed that Li^+ binds to $\text{ATP}\cdot\text{Mg}$, $\text{ADP}\cdot\text{Mg}$, and $\text{TP}\cdot\text{Mg}$, as well as other nucleo-

tides (Table S1) under saturating, stoichiometric Mg^{2+} binding conditions. Together, the data support an interaction of Li^+ through the polyphosphates that, as for Mg^{2+} , is electrostatically driven and guided by the cation's coordination geometry. Taken together, these results are important to how Li^+ may interact to form a “bioactive” species, as biological ATP is normally found in the Mg^{2+} bound state.

To measure the affinity of Li^+ for its binding site, the T1 of 2 mM LiCl was determined as a function of the concentration of the substrate (i.e., $\text{ATP}\cdot\text{Mg}$, $\text{ADP}\cdot\text{Mg}$, or $\text{TP}\cdot\text{Mg}$). The data in Fig. 2, A–C, show that increasing the substrate concentration shortened the ^7Li T1, reflecting a shift from free to substrate-bound Li^+ . Nonlinear least-squares fitting of the data yielded the apparent affinity of Li^+ for each substrate (Fig. 2, A–C). For example, the equilibrium dissociation constant (K_d) of Li^+ from $\text{ATP}\cdot\text{Mg}\cdot\text{Li}$ was found to be $1.6 \pm 0.21 \text{ mM}$ at 10°C . Interestingly, the measured Li^+ affinity for $\text{ATP}\cdot\text{Mg}$ is higher than the affinity of Li^+ for ATP alone ($K_d \sim 7.1 \text{ mM}$) (Fig. S3) or the Li^+ affinity for ATP previously reported using another competitive binding method (13). More importantly, the affinity determined here is relevant in view of the therapeutic Li^+ dosage (target serum level 0.8 – 1.1 mM (17)) as well as physiological concentrations of ATP and Mg^{2+} . Similarly, the affinity of Li^+ for ADP and TP in the presence of Mg^{2+} was measured and K_d 's are in the low-millimolar range (Fig. 2, A–C; Table S2). As expected, the affinity of Li^+ for $\text{ADP}\cdot\text{Mg}$ at 10°C ($K_d = 3.24 \pm 0.56 \text{ mM}$) was weaker than for $\text{ATP}\cdot\text{Mg}$, likely attributable to ADP having one fewer phosphate group and thus a reduced negative charge.




FIGURE 2 Measured affinity of Li^+ binding to $\text{ATP}\cdot\text{Mg}$, $\text{ADP}\cdot\text{Mg}$, and $\text{TP}\cdot\text{Mg}$. ^7Li T1 relaxation times (black circles) measured for 2 mM LiCl at 10°C as a function of the concentration of (A) $\text{ATP}\cdot\text{Mg}$, (B) $\text{ADP}\cdot\text{Mg}$, or (C) $\text{TP}\cdot\text{Mg}$ are shown. Fits using a quadratic binding equation (curves) yielded Li^+ equilibrium dissociation constants, K_d : $1.60 \pm 0.21 \text{ mM}$ for $\text{ATP}\cdot\text{Mg}$; $3.24 \pm 0.56 \text{ mM}$ for $\text{ADP}\cdot\text{Mg}$; and $0.71 \pm 0.23 \text{ mM}$ for $\text{TP}\cdot\text{Mg}$ (reported uncertainties are standard errors calculated from least-squares fitting). Sample integrity was monitored using ^{31}P NMR (Fig. S4). (D) A proposed molecular model for the ternary $\text{ATP}\cdot\text{Mg}\cdot\text{Li}$ complex is shown. Mg^{2+} is 6-coordinate, with the β and γ phosphate oxygens replacing two water molecules. Li^+ is 4-coordinate, with a γ phosphate oxygen replacing one water and a water bridge shared with Mg^{2+} . To see this figure in color, go online.

Interestingly, Li^+ affinity for $\text{TP}\cdot\text{Mg}$ was higher ($K_d = 0.71 \pm 0.23 \text{ mM}$) relative to $\text{ATP}\cdot\text{Mg}$, and further increased with temperature ($K_d = 0.31 \pm 0.16 \text{ mM}$ at 37°C). The temperature dependence of the binding affinity supports a model where binding is entropically driven, primarily through reorganization of the Li^+ hydration sphere. Further, the observation of an apparent higher affinity of Li^+ for $\text{TP}\cdot\text{Mg}$ relative to nucleotide $\cdot\text{Mg}$ could be explained by the fact that the TP is conformationally unconstrained by the nucleoside, has one extra negative charge on the second terminal phosphate and has effectively two terminal (PP) moieties for binding Mg^{2+} and Li^+ thus giving TP complex formation a statistical advantage. Together, this and other binding data (Table S2) support a model where Mg^{2+} binding to a phosphate moiety creates a secondary, “high-affinity” Li^+ binding site (Fig. 2 D), thus generating a two-metal-phosphate complex. The identified phosphate $\cdot\text{Mg}\cdot\text{Li}$ interaction points to the possibility, proposed in earlier work (5), that the pharmacologic mechanism of action of Li^+ could involve modulating normal ATP functions. The concept of a core phosphate $\cdot\text{Mg}\cdot\text{Li}$ interaction provides a common link between a number of previous studies that have identified seemingly unrelated kinases, phosphatases and other enzymes that have been proposed as potential targets for the action of Li^+ (10,18). Alternatively, the identified $\text{ATP}\cdot\text{Mg}\cdot\text{Li}$ complex raises the possibility that Li^+ could act by modulating ATP’s normal function as a receptor ligand. For example, purine ligands ATP or ADP bind and activate cell-surface purine receptors, of which there are two subtypes (Fig. 3 A): P2X, which are ion channels that mediate influx of extracellular Ca^{2+} into the cytoplasm, and P2Y, which are G-protein-coupled receptors (GPCRs) that activate the inositol trisphosphate second messenger pathway to release Ca^{2+} from intracellular stores (19–23). Modulation of purine receptor activity has been shown with different nucleotide analogs and metal cofactors (19,20,24).

To test the effect of Li^+ on P2 receptor activation, receptor responses in rat nodose ganglion neurons (12) were measured upon stimulation with $100 \mu\text{M}$ ATP in presence of 1.5 mM MgCl_2 , 1 mM LiCl , or both salts at these concentrations. Under these different conditions and using the binding affinities for each metal-ATP complex, the stimulating solution would be expected to contain $100 \mu\text{M}$ $\text{ATP}\cdot\text{Mg}$, and $63 \mu\text{M}$ $\text{ATP}\cdot\text{Mg}\cdot\text{Li}$, respectively. The change in cytosolic Ca^{2+} concentration ($[\text{Ca}^{2+}]_c$) upon P2 receptor activation was monitored with a fluorescent Ca^{2+} indicator, fluo-3 (25). After establishing that repeated ATP stimuli could reliably elicit P2 responses (Fig. 3 B), the responses to $\text{ATP}\cdot\text{Mg}$ and $\text{ATP}\cdot\text{Li}$ were compared with the response of ATP alone (Fig. 3 C). Although the Ca^{2+} response amplitudes were comparable for the three agents, the response elicited by $\text{ATP}\cdot\text{Li}$ is ~40% longer in duration than that elicited by ATP alone. Comparing the responses with $\text{ATP}\cdot\text{Mg}$ and $\text{ATP}\cdot\text{Mg}\cdot\text{Li}$ (Fig. 3 D) again showed comparable




FIGURE 3 Intracellular Ca^{2+} signals evoked by stimulating neuronal purinergic receptors with ATP, $\text{ATP}\cdot\text{Mg}$, $\text{ATP}\cdot\text{Li}$, and $\text{ATP}\cdot\text{Mg}\cdot\text{Li}$. (A) Schematic representation of purinergic receptors on the cell surface: P2X receptors are ion channels that permit influx of Ca^{2+} ions when activated by purinergic ligands like ATP; P2Y receptors are G-protein-coupled and trigger Ca^{2+} release from intracellular stores when activated by ATP. (B) Ca^{2+} signals are reliably triggered by consecutive 20 s pulses of $100 \mu\text{M}$ ATP. Repeated responses in the same cell are not significantly different (compare 1st and 2nd responses: $t_{100-20} = 114, 112 \text{ s}$, respectively, $p = 0.83$, $n = 9$). (C) Ca^{2+} signals elicited by 20 s pulses of $100 \mu\text{M}$ $\text{ATP}\cdot\text{Mg}$, $100 \mu\text{M}$ ATP, or $100 \mu\text{M}$ $\text{ATP}\cdot\text{Li}$. $\text{ATP}\cdot\text{Li}$ without Mg^{2+} lengthens the Ca^{2+} response by 39% (compare 2nd and 3rd responses (ATP vs. $\text{ATP}\cdot\text{Li}$, $[\text{Mg}^{2+}] = 0 \text{ mM}$): mean $t_{100-20} = 139, 193 \text{ s}$, respectively, $p = 0.015$, $n = 12$). (D) Ca^{2+} responses evoked by 20 s pulses of $100 \mu\text{M}$ $\text{ATP}\cdot\text{Mg}$ or $100 \mu\text{M}$ $\text{ATP}\cdot\text{Mg}\cdot\text{Li}$. Response evoked by $\text{ATP}\cdot\text{Mg}\cdot\text{Li}$ was longer than that evoked by $\text{ATP}\cdot\text{Mg}$ by 2.2-fold (compare 1st and 2nd responses ($\text{ATP}\cdot\text{Mg}$ vs. $\text{ATP}\cdot\text{Mg}\cdot\text{Li}$): $t_{100-20} = 86, 191 \text{ s}$, respectively, $p = 2.4 \times 10^{-5}$, $n = 20$; compare 1st and 3rd response (1st $\text{ATP}\cdot\text{Mg}$ vs. 2nd $\text{ATP}\cdot\text{Mg}$; internal control): $t_{100-20} = 86, 88 \text{ s}$, respectively, $p = 0.78$, $n = 20$). (E) Ca^{2+} responses triggered by 100 s pulses of $100 \mu\text{M}$ $\text{ATP}\cdot\text{Mg}$ or $100 \mu\text{M}$ $\text{ATP}\cdot\text{Mg}\cdot\text{Li}$ in Ca^{2+} -free buffer. The P2Y component of ATP response does not depend significantly on Li^+ (compare 1st and 2nd responses ($\text{ATP}\cdot\text{Mg}$ vs. $\text{ATP}\cdot\text{Mg}\cdot\text{Li}$): $t_{100-20} = 41, 50 \text{ s}$, respectively, $p = 0.17338$, $n = 28$; compare 1st and 3rd responses (1st $\text{ATP}\cdot\text{Mg}$ vs. 2nd $\text{ATP}\cdot\text{Mg}$; internal control): $t_{100-20} = 41, 38 \text{ s}$, respectively, $p = 0.73$, $n = 28$). In panels B–D, extracellular Ca^{2+} was 2.5 mM . Application of Li^+ alone elicited no response (not shown).

amplitudes, but notably, the response to the ternary complex, ATP·Mg·Li, lasted about twice as long as the response to ATP·Mg. The longer response could be due to prolonged Ca²⁺ influx through P2X receptors, or prolonged P2Y receptor signaling triggering greater intracellular Ca²⁺ release. These alternatives can be distinguished by applying the stimuli in the absence of extracellular Ca²⁺, which abolishes Ca²⁺ influx (Fig. 3 E). In Ca²⁺-free medium, not only were the responses to ATP·Mg and ATP·Mg·Li comparable in amplitude, their temporal durations were also not significantly different. As absence of extracellular Ca²⁺ permits only P2Y-mediated Ca²⁺ responses, this experiment indicates that ATP·Mg and ATP·Mg·Li activate P2Y receptors comparably. Therefore, that ATP·Mg·Li evoked a longer Ca²⁺ response than ATP·Mg in Ca²⁺-containing medium implies that P2X receptor activation is prolonged when ATP·Mg·Li is the stimulus.

CONCLUSIONS

The observation that Li⁺ can interact directly with magnesium-phosphates (e.g., ATP·Mg·Li) and modulate P2 receptor response, suggests a mode of *in vivo* Li⁺ action through ligand-activated cell surface receptors, which could modulate signaling in the central nervous system and the periphery. Although our data cannot rule out an off-target effect of Li⁺ in these experiments, the interpretation that Li⁺ exerts its effect through the ATP·Mg·Li complex is consistent with previous studies that have demonstrated a specific modulatory effect of magnesium binding to ATP on activation of different purine receptor subtypes (20,21,26).

For any putative bioactive form of Li⁺ to be clinically relevant, it should exist in appreciable proportions under the low dosing levels of Li⁺ (17,27). Our studies indicate that a considerable fraction of the ATP·Mg·Li complex could form at normal ATP and Mg²⁺ concentrations found in the plasma or cytoplasm (Table S3). Moreover, elevated ATP levels corresponding to biological activity or stress response in the cytoplasm, organelles (e.g., mitochondria), and the extracellular matrix could serve as reservoirs for accumulating Li⁺.

In summary, the ATP·Mg·Li complex provides a way to broadly view lithium's bioactive form as acting through cobinding with Mg²⁺ to phosphate-containing ligands or cofactors of receptors and enzymes. This general molecular model provides a new perspective, to our knowledge, to direct the identification of Li⁺ targets, guide drug design, and contribute to advancing our understanding of lithium's pharmacology.

SUPPORTING MATERIAL

Four figures and three tables are available at [http://www.biophysj.org/biophysj/supplemental/S0006-3495\(16\)30461-1](http://www.biophysj.org/biophysj/supplemental/S0006-3495(16)30461-1).

AUTHOR CONTRIBUTIONS

K.T.B., G.G.G., and J.P.M. conceived the study. K.T.B. and G.G.G. performed the NMR experiments. G.L. and J.P.Y.K. performed the neuronal measurements. K.T.B., J.P.Y.K., and J.P.M. wrote the article.

ACKNOWLEDGMENTS

We acknowledge NIST and W.M. Keck for support of NMR instrumentation. We thank Dr. Nese Sari (UMD) for support with NMR experiments.

This work was supported by grants from the NIH, GM056481 (J.P.Y.K.) and UMD Dean's Matching Fund for NIH Training Grant in Cell and Molecular Biology, T32GM080201 (K.T.B.).

SUPPORTING CITATIONS

References (28–31) appear in the [Supporting Material](#).

REFERENCES

- Pearson, I. B., and F. A. Jenner. 1971. Lithium in psychiatry. *Nature*. 232:532–533.
- Cade, J. F. J. 1949. Lithium salts in the treatment of psychotic excitement. *Med. J. Aust.* 2:349–352.
- Frausto da Silva, J. J., and R. J. Williams. 1976. Possible mechanism for the biological action of lithium. *Nature*. 263:237–239.
- Schwarzenbach, G., E. Kampitsch, and R. Steiner. 1946. Komplexe III. Uramil-diessigsäure und ihr Komplexbildungsvermögen. *Helv. Chim. Acta*. 29:364–370.
- Birch, N. J., and I. Goulding. 1975. Lithium-nucleotide interactions investigated by gel filtration. *Anal. Biochem.* 66:293–297.
- Birch, J. 1976. Possible mechanism for biological action of lithium. *Nature*. 264:681.
- Abraha, A., D. E. de Freitas, ..., C. F. G. C. Gerales. 1991. Competition between Li⁺ and Mg²⁺ for ATP and ADP in aqueous solution: a multinuclear NMR study. *J. Inorg. Biochem.* 42:191–198.
- Mota de Freitas, D., M. M. Castro, and C. F. Gerales. 2006. Is competition between Li⁺ and Mg²⁺ the underlying theme in the proposed mechanisms for the pharmacological action of lithium salts in bipolar disorder? *Acc. Chem. Res.* 39:283–291.
- Brown, S. G., R. M. Hawk, and R. A. Komoroski. 1993. Competition of Li(I) and Mg(II) for ATP binding: a ³¹P NMR study. *J. Inorg. Biochem.* 49:1–8.
- Quiroz, J. A., T. D. Gould, and H. K. Manji. 2004. Molecular effects of lithium. *Mol. Interv.* 4:259–272.
- Leal-Cardoso, H., G. M. Koschorke, ..., D. Weinreich. 1993. Electrophysiological properties and chemosensitivity of acutely isolated nodose ganglion neurons of the rabbit. *J. Auton. Nerv. Syst.* 45:29–39.
- Hoesch, R. E., K. Yienger, ..., J. P. Y. Kao. 2002. Coexistence of functional IP₃ and ryanodine receptors in vagal sensory neurons and their activation by ATP. *J. Neurophysiol.* 88:1212–1219.
- Wilson, J. E., and A. Chin. 1991. Chelation of divalent cations by ATP, studied by titration calorimetry. *Anal. Biochem.* 193:16–19.
- Niccolai, N., E. Tiezzi, and G. Valensin. 1982. Manganese(II) as magnetic relaxation probe in the study of biomechanisms and of biomacromolecules. *Chem. Rev.* 82:359–384.
- Cowan, J. A. 1991. Metallobiochemistry of magnesium. Coordination complexes with biological substrates: site specificity, kinetics and thermodynamics of binding, and implications for activity. *Inorg. Chem.* 30:2740–2747.

16. Sari, J. C., and J. P. Belaich. 1973. Microcalorimetric studies on the formation of magnesium complexes with 5 ribonucleotides of guanine, uracil, and hypoxanthine. *J. Am. Chem. Soc.* 95:7491–7496.
17. Yatham, L. N., S. H. Kennedy, ..., C. P. Gorman. 2005. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. *Bipolar Disord.* 7 (Suppl. 3):5–69.
18. Ryves, W. J., R. Dajani, ..., A. J. Harwood. 2002. Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. *Biochem. Biophys. Res. Commun.* 290:967–972.
19. Burnstock, G. 2016. An introduction to the roles of purinergic signaling in neurodegeneration, neuroprotection and neuroregeneration. *Neuropharmacology.* 104:4–17.
20. Li, M., S. D. Silberberg, and K. J. Swartz. 2013. Subtype-specific control of P2X receptor channel signaling by ATP and Mg^{2+} . *Proc. Natl. Acad. Sci. USA.* 110:E3455–E3463.
21. Kasuya, G., Y. Fujiwara, ..., O. Nureki. 2016. Structural insights into divalent cation modulations of ATP-gated P2X receptor channels. *Cell Reports.* 14:932–944.
22. Sperlágh, B., and P. Illes. 2014. P2X7 receptor: an emerging target in central nervous system diseases. *Trends Pharmacol. Sci.* 35:537–547.
23. Hattori, M., and E. Gouaux. 2012. Molecular mechanism of ATP binding and ion channel activation in P2X receptors. *Nature.* 485:207–212.
24. Jacobson, K. A., M. F. Jarvis, and M. Williams. 2002. Purine and pyrimidine (P2) receptors as drug targets. *J. Med. Chem.* 45:4057–4093.
25. Minta, A., J. P. Kao, and R. Y. Tsien. 1989. Fluorescent indicators for cytosolic calcium based on rhodamine and fluorescein chromophores. *J. Biol. Chem.* 264:8171–8178.
26. Salas, E., L. M. G. Carrasquero, ..., E. G. Delicado. 2013. Purinergic P2X7 receptors mediate cell death in mouse cerebellar astrocytes in culture. *J. Pharmacol. Exp. Ther.* 347:802–815.
27. Birch, N. J. 1991. Lithium and the Cell: Pharmacology and Biochemistry. Academic Press, Boston.
28. Gorman, M. W., E. O. Feigl, and C. W. Buffington. 2007. Human plasma ATP concentration. *Clin. Chem.* 53:318–325.
29. Traut, T. W. 1994. Physiological concentrations of purines and pyrimidines. *Mol. Cell. Biochem.* 140:1–22.
30. Ando, T., H. Imamura, ..., T. Suzuki. 2012. Visualization and measurement of ATP levels in living cells replicating hepatitis C virus genome RNA. *PLoS Pathog.* 8:e1002561.
31. Idzko, M., D. Ferrari, and H. K. Eltzschig. 2014. Nucleotide signalling during inflammation. *Nature.* 509:310–317.